
Cosmica Biosciences focuses on accelerating drug discovery for longevity by utilizing unbiased multi-scale biology and machine learning algorithms. The company aims to develop precision-based interventions to extend human lifespan and mitigate health risks associated with spaceflight. Their platform leverages data from human blood and organoids exposed to microgravity and galactic radiation, as well as in vivo data from commercial and non-commercial crew members and NASA experiments. This unique approach positions Cosmica at the intersection of aging research and space biology, offering significant potential for breakthroughs in anti-aging therapeutics.

Cosmica Biosciences focuses on accelerating drug discovery for longevity by utilizing unbiased multi-scale biology and machine learning algorithms. The company aims to develop precision-based interventions to extend human lifespan and mitigate health risks associated with spaceflight. Their platform leverages data from human blood and organoids exposed to microgravity and galactic radiation, as well as in vivo data from commercial and non-commercial crew members and NASA experiments. This unique approach positions Cosmica at the intersection of aging research and space biology, offering significant potential for breakthroughs in anti-aging therapeutics.
Focus: Accelerating drug discovery for longevity using multi-scale biology and machine learning
Founded: 2022
HQ: San Francisco, CA
Early funding: Pre-Seed round led by Longevitytech.fund (Jun 26, 2023)
Team size (reported): 5 employees
Aging biology, longevity therapeutics, and spaceflight-associated health risks
2022
Biotechnology
“Longevitytech.fund as reported lead investor for Pre-Seed round”